Abstract
In the beginning, SGLT2 inhibitors were regarded as anti-diabetic agents. But after demonstration of the cardiovascular benefit of SGLT2 inhibitors in EMPAREG-OUTCOME trial, a whole new era of heart failure therapy opened up. It became an integral part of heart failure treatment protocol. Several studies demonstrated its beneficial role in HFrEF until EMPEROR PRESERVED trail. It showed the benefit of SGLT2 inhibitors in HFpEF group of patients. It was consolidated by PRESERVED HF trial and recently concluded DELIVER trial. SGLT2 inhibitors are a single group of medication that is effective in all types of heart failure patients irrespective of their ejection fraction and diabetic status. Several mechanisms of action of SGLT2 inhibitors have been proposed that can explain its cardiovascular benefits. But still, studies to elucidate molecular and genetic mechanisms are going on which may open newer avenues of heart failure management in the future.
Keywords
Heart failure, SGLT2 inhibitors, Review, Trials